m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG00269)
Name
Briciclib
Synonyms
Briciclib; 865783-99-9; ON-014185; UNII-WG93X96336; WG93X96336; ON 014185; Briciclib [USAN:INN]; Briciclib (USAN/INN); Briciclib; ON 014185; SCHEMBL1634579; SCHEMBL1634581; CHEMBL1206245; MolPort-046-033-539; LXENKEWVEVKKGV-BQYQJAHWSA-N; EX-A2492; BCP17292; ZINC28965775; AKOS027439966; DB12004; CS-5589; HY-16366; KB-79924; Briciclib(ON 013105 ON 014185); ON-013105; D10614; (2-methoxy-5-{[(E)-2-(2,4,6-trimethoxyphenyl)ethenesulfonyl]methyl}phenoxy)phosphonic acid; (e)-5-((2,4,6-trimethoxystyrylsulfonyl)methyl)-2-methoxyphenyl dihydro
    Click to Show/Hide
Status
Phase 1
Structure
Formula
C19H23O10PS
InChI
1S/C19H23O10PS/c1-25-14-10-17(27-3)15(18(11-14)28-4)7-8-31(23,24)12-13-5-6-16(26-2)19(9-13)29-30(20,21)22/h5-11H,12H2,1-4H3,(H2,20,21,22)/b8-7+
InChIKey
LXENKEWVEVKKGV-BQYQJAHWSA-N
PubChem CID
11248490
TTD Drug ID
D0T0KT
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
G1/S-specific cyclin-D1 (CCND1)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary G1/S-specific cyclin-D1 (CCND1) is a therapeutic target for Briciclib. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Briciclib through regulating the expression of G1/S-specific cyclin-D1 (CCND1). [1], [2]
Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary G1/S-specific cyclin-D1 (CCND1) is a therapeutic target for Briciclib. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of Briciclib through regulating the expression of G1/S-specific cyclin-D1 (CCND1). [2], [3]
Methyltransferase-like 16 (METTL16)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary G1/S-specific cyclin-D1 (CCND1) is a therapeutic target for Briciclib. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of Briciclib through regulating the expression of G1/S-specific cyclin-D1 (CCND1). [2], [4]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary G1/S-specific cyclin-D1 (CCND1) is a therapeutic target for Briciclib. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Briciclib through regulating the expression of G1/S-specific cyclin-D1 (CCND1). [2], [5]
Protein virilizer homolog (VIRMA)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary G1/S-specific cyclin-D1 (CCND1) is a therapeutic target for Briciclib. The Protein virilizer homolog (VIRMA) has potential in affecting the response of Briciclib through regulating the expression of G1/S-specific cyclin-D1 (CCND1). [2], [3]
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary G1/S-specific cyclin-D1 (CCND1) is a therapeutic target for Briciclib. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Briciclib through regulating the expression of G1/S-specific cyclin-D1 (CCND1). [2], [6]
YTH domain-containing family protein 2 (YTHDF2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary G1/S-specific cyclin-D1 (CCND1) is a therapeutic target for Briciclib. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Briciclib through regulating the expression of G1/S-specific cyclin-D1 (CCND1). [1], [2]
References
Ref 1 FTO regulates myoblast proliferation by controlling CCND1 expression in an m(6)A-YTHDF2-dependent manner. Exp Cell Res. 2021 Apr 15;401(2):112524. doi: 10.1016/j.yexcr.2021.112524. Epub 2021 Feb 27.
Ref 2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 3 Identification of pathology-specific regulators of m(6)A RNA modification to optimize lung cancer management in the context of predictive, preventive, and personalized medicine. EPMA J. 2020 Jul 29;11(3):485-504. doi: 10.1007/s13167-020-00220-3. eCollection 2020 Sep.
Ref 4 METTL16 promotes cell proliferation by up-regulating cyclin D1 expression in gastric cancer. J Cell Mol Med. 2021 Jul;25(14):6602-6617. doi: 10.1111/jcmm.16664. Epub 2021 Jun 2.
Ref 5 METTL3 serves an oncogenic role in human ovarian cancer cells partially via the AKT signaling pathway. Oncol Lett. 2020 Apr;19(4):3197-3204. doi: 10.3892/ol.2020.11425. Epub 2020 Mar 3.
Ref 6 YTHDF1 links hypoxia adaptation and non-small cell lung cancer progression. Nat Commun. 2019 Oct 25;10(1):4892. doi: 10.1038/s41467-019-12801-6.